What You Should Know:
– Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics announced the publication of foundational preclinical data in the peer-reviewed journal Cell Reports Medicine, the close of a $25M Series A1 financing round.
– In addition, the company appointed Dr. Thomas A. Buchholz as a clinical advisor. The funding brings the total raised in Series A financing to $40M.
Foundational Preclinical Data Validates Cancer-Selective Mechanism
The published study provides the most comprehensive validation to date of the ELANE pathway as a cancer-selective, immune-activating mechanism. Onchilles’ lead drug candidate, N17350, is a tumor-directed biologic that leverages this pathway to selectively kill cancer cells while sparing healthy tissue and activating a systemic immune response.
- Broad Efficacy: N17350 demonstrated consistent monotherapy efficacy, immune cell sparing, and durable responses across 30 cancer cell lines and 15 in vivo models, including chemotherapy-resistant cells and immunologically “cold” tumors.
- Dual Mechanism: The data highlight N17350’s ability to drive direct tumor killing (through mitochondrial and DNA damage) and CD8+ T cell-mediated immune activation by targeting elevated histone H1 levels, a vulnerability found in many malignant cancer cells.
- Targeted Scope: Preclinical results showed rapid, selective tumor killing and immune activation across models of breast, lung, ovarian, colon, and other cancers.
Lev Becker, Ph.D., Co-Founder and Chief Scientific Officer, stated, “We believe our next-generation cytotoxic therapeutics that harness the ELANE pathway offer a compelling new treatment breakthrough that combines cytotoxic activity with immune-preserving activity and the potential to address a broad range of solid tumors”.
N17350 Enters Clinical Phase with Clear Milestones
The $25M Series A1 financing is dedicated to funding the N17350 program through clinical proof-of-concept, expected by the second half of 2026.
- Trial Initiation: Onchilles plans to initiate a first-in-human trial of N17350, a tumor-directed injectable, in patients in Australia early next year.
- U.S. Expansion: IND clearance in the United States and U.S. patient enrollment are expected in mid-2026. The study will evaluate safety, monotherapy activity, and biomarkers of immune activation across multiple solid tumor types, including breast, skin, and head and neck cancers.
- Manufacturing Readiness: The company has successfully completed a GMP manufacturing campaign with over 5,000 doses of N17350 available for clinical use.
Court R. Turner, J.D., Co-Founder and CEO of Onchilles, noted, “We are well-positioned to demonstrate clinical activity, and if that data looks anything like our preclinical results, we believe N17350 could represent a breakthrough therapeutic class with relevance across a variety of solid tumors”.
